Arvinas, Inc. Common Stock (ARVN) Stock
NASDAQ · ARVN
7.46
Fundamentals
Market cap
$496.28M
Price / Earnings ratio
54.8x
Price / Sales ratio
1.6x
Price / Book ratio
0.9x
Return on assets
-28.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
NeutralARVNAugust 6, 2026
Zacks Investment ResearchNeutral
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
ARVN

MarketBeat
Arvinas Q2 Earnings Call Highlights
NeutralARVNAugust 4, 2026
MarketBeatNeutral
Arvinas Q2 Earnings Call Highlights
ARVN

Zacks Investment Research
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
NeutralARVNAugust 4, 2026
Zacks Investment ResearchNeutral
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
ARVN

MarketBeat
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
NeutralARVNJune 5, 2026
MarketBeatNeutral
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
ARVN
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral2
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
315M208M104M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
861M569M284M0
Revenue to Profit
2025$262.6M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-80.8M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
NeutralARVNAugust 6, 2026
Zacks Investment ResearchNeutral
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
ARVN

MarketBeat
Arvinas Q2 Earnings Call Highlights
NeutralARVNAugust 4, 2026
MarketBeatNeutral
Arvinas Q2 Earnings Call Highlights
ARVN

Zacks Investment Research
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
NeutralARVNAugust 4, 2026
Zacks Investment ResearchNeutral
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
ARVN

MarketBeat
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
NeutralARVNJune 5, 2026
MarketBeatNeutral
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
ARVN

Stocktwits
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?
NeutralARVNMay 12, 2026
StocktwitsNeutral
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?
ARVN

MarketBeat
Arvinas Q1 Earnings Call Highlights
NeutralARVNMay 12, 2026
MarketBeatNeutral
Arvinas Q1 Earnings Call Highlights
ARVN

Zacks Investment Research
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
NeutralARVNMay 12, 2026
Zacks Investment ResearchNeutral
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
ARVN

Reuters
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
NeutralARVNMay 12, 2026
ReutersNeutral
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
ARVN

Stocktwits
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule
NeutralARVNMay 1, 2026
StocktwitsNeutral
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule
ARVN

Reuters
US FDA approves Pfizer, Arvinas' breast cancer drug
NeutralARVNMay 1, 2026
ReutersNeutral
US FDA approves Pfizer, Arvinas' breast cancer drug
ARVN
About Arvinas, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees246
CEODr. Randy Teel Ph.D.
IPO DateSep 27, 2018
HeadquartersNew Haven, CT
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew R. Saik | CFO & Treasurer | 1969 |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer | 1968 |
| Dr. Randy Teel Ph.D. | CEO, President & Director | 1980 |
| Mr. David K. Loomis M.B.A. | VP & Chief Accounting Officer | 1974 |
| Mr. Jeff Boyle | Vice President of Investor Relations | — |
| Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary | 1969 |
| Mr. Steve Weiss | Senior VP & Chief Human Resources Officer | 1970 |
| Mr. Paul McInulty | Senior Vice President of Regulatory Affairs | — |
| Ms. Kelly Page | Senior VP & Global Head of Oncology Strategy and Program Leadership | — |
Fundamentals
Valuation
Market cap$496.28M
Price-to-sales ratio1.61
Price-to-book value0.91
Price-earnings ratio54.80
Return on Equity-44.00%
Return on Sales-247.00%
Return on Assets-28.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$0.27
Income Statement
Average volume826,664
EBITDA$-216.00M
1 year high (52w)$14.51
1 year low (52w)$6.97
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
60% Buy
40% Hold
0% Sell
Target price
$15.20
Est return
99.74%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.5 | +1.6 | -14.9 | +8.3 | ||||||||
| 2022 | -12.4 | -7.5 | +2.4 | -21.5 | -25.6 | +2.8 | +24.7 | -16.0 | +2.1 | +16.1 | -20.0 | -13.9 |
| 2023 | -1.8 | -8.4 | -10.6 | -8.1 | -19.3 | +14.2 | -1.8 | +13.5 | -29.5 | -14.4 | +37.5 | +74.4 |
| 2024 | +0.0 | +0.7 | -12.7 | -21.4 | +2.0 | -4.6 | +5.9 | -2.3 | -3.4 | +6.2 | -0.7 | -25.5 |
| 2025 | -6.8 | +3.5 | -56.7 | +36.8 | -0.4 | +0.4 | -2.5 | +4.2 | +7.8 | +11.1 | +29.5 | +0.4 |
| 2026 | +16.7 | -4.0 | -20.8 | -12.6 | -14.6 | -3.1 | -2.1 | +14.1 | -18.2 |



